BIOMARKERS IN EARLY ALZHEIMER'S DISEASE

早期阿尔茨海默病的生物标志物

• 批准号: 7605727
• 负责人: MONY J. de LEON
• 金额: $ 1.3万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605727
• 关键词: Alzheimer' s Disease; Amyloid beta-Protein; Atrophic; Biological Markers; Computer Retrieval of Information on Scientific Projects Database; Data; Elderly; Enrollment; Evaluation; Funding; Grant; Hippocampus (Brain); Image; Impaired cognition; Individual; Institution; Invasive; Magnetic Resonance Imaging; Measurement; Measures; Memory; Neurofibrillary Tangles; Neurons; Research; Research Personnel; Resources; Source; Specificity; Spinal Puncture; Spinal Tap; Testing; United States National Institutes of Health; base; entorhinal cortex; improved; neuropsychological; size; tau Proteins; tau mutation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It would be highly desirable to develop a non-invasive test for Alzheimer's disease (AD). The aim of this study is to use MRI and CSF biomarkers to identify in normal subjects the earliest clinically detected changes of AD. The hypothesis is that CSF P-tau levels will improve accuracy of MRI measurements of atrophy and CSF amyloid-beta measurements as a predictor of decline to cognitive impairment. The study is based on the observation that in some normal and minimally cognitively impaired individuals, neuronal and volume loss in the entorhinal cortex can be seen in association with neurofibrillary tangles. Imaging studies lack specificity, but the investigators suggest that tangle-related abnormal tau proteins (P-tau 231) are elevated in the CSF of minimally cognitively impaired individuals, predicting decline, and are specific for AD. This is a longitudinal MRI and CSF study over 3 years (3 evaluations) on 80 elderly normal subjects (50 with memory complaints) already enrolled in another study. MRI will be performed to measure hippocampus size. Lumbar puncture will be done to measure tau and amyloid-beta proteins. Standardized neuropsychological data will also be collected.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 开发一种针对阿尔茨海默病（AD）的非侵入性测试是非常可取的。 本研究的目的是使用MRI和CSF生物标志物来识别正常受试者中最早临床检测到的AD变化。 假设CSF P-tau水平将提高萎缩的MRI测量和CSF淀粉样蛋白β测量的准确性，作为认知障碍下降的预测因子。 该研究基于以下观察结果：在一些正常和轻度认知障碍的个体中，可以看到内嗅皮层中的神经元和体积损失与神经元缠结相关。 影像学研究缺乏特异性，但研究人员认为，缠结相关的异常tau蛋白（P-tau 231）在最小认知障碍个体的CSF中升高，预测下降，并且对AD具有特异性。 这是一项对已入组另一项研究的80例老年正常受试者（50例有记忆投诉）进行的为期3年（3次评价）的纵向MRI和CSF研究。 将进行MRI以测量海马大小。 将进行腰椎穿刺以测量tau和淀粉样β蛋白。 还将收集标准化的神经心理学数据。